Infertile/subfertile couples
Advanced maternal age (egg freezing, donor eggs)
Fertility preservation before medical treatment
Recurrent miscarriage/ implantation failure
Cross-border fertility care
Since 2020, Taipei Fertility Center (TFC) has been dedicated to patient-centered reproductive medicine, guided by five core values: Humanity, Excellence, Social Responsibility, Sustainability, and Global Collaboration.
Over the past five years, TFC has provided care to more than 30,000 infertility patients from nearly 50 countries, resulting in over 3,000 live births. With more than 100 conference presentations, including 17 that have received top awards from major reproductive societies in the United States, Europe, the Asia-Pacific region, and Taiwan, TFC has demonstrated a strong and sustained academic impact.
TFC actively collaborates with leading institutions, including Harvard University, the University of Ottawa, and the University of Tokyo, as well as with global pharmaceutical companies on international clinical and academic research projects. Its proprietary probiotic products, ZOEY.J and PVITA, received the 2024 Silver Award and 2025 Gold Award, respectively, from Monde Selection.
With an IVF live birth rate of 54.6% in women under 38 years of age, and more than 500 Google reviews with an average rating of 4.5 stars, TFC continues to showcase Taiwan’s strengths in reproductive medicine on the global stage, offering renewed hope to couples worldwide.
Establishment of standardized clinical procedures through a dedicated data management system and the "TFC Assistant App" to enhance medical workflow efficiency and quality of care.
Personalized treatment for patients of advanced maternal age: By integrating preimplantation genetic testing for aneuploidy (PGT-A) and next-generation sequencing–based endometrial receptivity analysis (ERA), the pregnancy rate was increased from 25% to 47.5%. Probiotic supplementation to optimize the uterine microbiota further increased the pregnancy rate from 42.5% to 71.4% in patients with recurrent implantation failure (RIF).
Using time-lapse incubator technology combined with a non-invasive, AI-based embryo viability prediction system.
Customized treatment protocols, including growth hormone supplementation for patients with poor ovarian response, GnRH agonist pre-treatment for endometriosis, and the use of Atosiban prior to embryo transfer.
An integrated clinic combining traditional Chinese medicine and Western medicine to provide comprehensive fertility care.
Multilingual medical services are available to support international patients, with specialists fluent in Chinese, English, Japanese, Cantonese, Korean, and Burmese.
Since 2020, TFC has supported more than 30,000 patients from nearly 50 countries seeking fertility treatment in Taiwan.
Over 12,000 IVF retrieval or egg-freezing procedures have been performed.
More than 3,000 babies have been successfully born.
The overall live birth rate per transfer cycle across all age groups is 45.5%, exceeding Taiwan’s national average of 32.5%.
For women under 38 years of age, the live birth rate reaches 54.6%.
For women over 40 years of age, the live birth rate is 26.7%, significantly higher than that reported by best Fertility Center in the United States (15.1%).
Oocyte thawing survival exceeds 95%, and embryo thawing survival reaches 99%.
An intelligent queuing system enhances patient experience by reducing waiting time by approximately 2.5 hours.
The embryology laboratory is designed in accordance with the “Cairo Consensus”, with strict control over VOCs, temperature and humidity, and a high standard of aseptic environment.
Laboratory imaging monitoring device and liquid nitrogen tank monitoring sensors ensure equipment safety.
Conduction of weekly clinical case discussions and literature sharing, along with regular training for laboratory and medical staff.
From 2022 to 2025, the incidence of unexpected medical needs or post-retrieval complications was approximately 0.3%–0.6%.
Well-established partner hospitals in Taipei and New Taipei City provide prompt emergency medical support when needed.
Over 500 Google reviews with an average rating of 4.5 stars.
A healthcare quality satisfaction survey conducted between 2024 and 2025 reported an average satisfaction rate of 95.65%.
TFC leadership serves as president and secretary-general of major international reproductive medicine societies, including WES, ISFP, and ASPIRE.
Serves as Associate Editor of HR Open, Associate Editor of JVOR, and Editor of RBMO.
Founder of TFC, recipient of the “Medical Contribution Lifetime Achievement Awards” from Global Chinese GCARM and IMDA.
Led a large-scale AMH study across 10 Asia Pacific countries, with the results published in Human Reproduction journal.
In the past five years, 24 SCI journal articles have been published in the field of reproductive medicine.
Over 100 conference papers have been presented worldwide, with 17 receiving awards at conferences in the United States, the Asian Pacific region, and Taiwan.
Regularly invite international experts to give lectures and visit TFC
Active collaborations with leading fertility clinics in the United States (Boston IVF etc) for physician exchange and training, and Japan (Saint mother etc.) for follow-up services before and after embryo transfer.
In collaboration with the Taiwan Egg Freezing Association (TEFA), launched the “Public Welfare Hope Project” to support cancer patients for preserving their fertility.
Regularly host multiple public-interest and corporate seminars each year to promote public education.
TFC conducted a special opinion survey on the Amendment of the “Assisted Reproduction Act”, urging the government to recognize the importance of legislative reform.
In partnership with Taipei Medical University, launched a micro program in reproductive medicine to train future professionals in the field.
Published five books on reproductive medicine to enhance public understanding and awareness.
